Sort by
Refine Your Search
-
are the leader in RNAi therapeutics – a revolutionary approach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science, Alnylam has delivered
-
competencies in core areas of MSA functions, such as Publications and Scientific Communications, Field Medical Affairs (Medical Science Liaison), Medical Information, Medical Education, and Evidence Generation
-
, and scholarly activities. In partnership with Northeastern University, Intellia Therapeutics is offering a two-year Health economics and outcomes research (HEOR) fellowship, based in Cambridge, MA
-
facility in Kendall Square. About AstraZeneca At AstraZeneca, we’re dedicated to being a Great Place to Work, where you’re empowered to push the boundaries of science and unleash your entrepreneurial spirit
-
as medical communications, publications, medical information, and congress planning, the fellow will engage in global cross-functional collaboration, contribute to the communication of emerging science
-
substantial opportunity to shape research direction and develop independent lines of investigation in an emerging area at the interface of microbiology, materials science, and electronics. Research Environment
-
, bioCSL. The Medical Affairs fellow will assist across all pertinent areas of medical affairs within CSL Seqirus. The fellow will have rotations in medical information, publications, scientific
-
on Nobel Prize-winning science, Alnylam has delivered the breakthroughs that made RNAi therapeutics possible and are just at the beginning of what’s possible. Our deep pipeline, late-stage programs, and bold
-
also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy
-
who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug